Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Soffer

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
JACC. Cardiovascular Interventions|August 23, 2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) StudyFrancesco Franchi, Fabiana Rollini, Luis Ortega-Paz, et al.
Thrombosis and Haemostasis|January 4, 2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic DiseaseMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
JACC. Basic to Translational Science|August 22, 2024
Clopidogrel-Mediated P2Y<sub>12</sub> Inhibition According to Renal Function in Patients With Diabetes Mellitus and CADLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
JACC. Basic to Translational Science|January 31, 2020
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 StudyFrancesco Franchi, Fabiana Rollini, Victor Kairouz, et al.
Journal of the American Heart Association|April 21, 2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y<sub>12</sub> Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC StudyFrancesco Franchi, Fabiana Rollini, Gabriel Faz, et al.
JACC. Cardiovascular Interventions|April 10, 2024
P2Y<sub>12</sub> Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 StudyLuis Ortega-Paz, Wilbert Bor, Francesco Franchi, et al.
JAMA Cardiology|January 3, 2020
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action, Katherine A Wilemon, Jasmine Patel, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
JACC. Cardiovascular Interventions|August 23, 2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) StudyFrancesco Franchi, Fabiana Rollini, Luis Ortega-Paz, et al.
Thrombosis and Haemostasis|January 4, 2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic DiseaseMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
JACC. Basic to Translational Science|August 22, 2024
Clopidogrel-Mediated P2Y<sub>12</sub> Inhibition According to Renal Function in Patients With Diabetes Mellitus and CADLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
JACC. Basic to Translational Science|January 31, 2020
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 StudyFrancesco Franchi, Fabiana Rollini, Victor Kairouz, et al.
Journal of the American Heart Association|April 21, 2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y<sub>12</sub> Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC StudyFrancesco Franchi, Fabiana Rollini, Gabriel Faz, et al.
JACC. Cardiovascular Interventions|April 10, 2024
P2Y<sub>12</sub> Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 StudyLuis Ortega-Paz, Wilbert Bor, Francesco Franchi, et al.
JAMA Cardiology|January 3, 2020
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action, Katherine A Wilemon, Jasmine Patel, et al.
Pageof 4